Check your eligibility now & get in touch with a study center

CHECK ELIGIBILITY

Do you have atopic dermatitis?

Sanofi believes that everyone should have the opportunity to take part in clinical trials. It is important to include people who have been historically under-represented in clinical trials.

Sanofi is committed to inclusivity in our studies. If you are interested in learning more about this study, we encourage you to complete a brief questionnaire to help determine if you may qualify to participate and be referred to a site recruiting in your area for further evaluation.
Tanya, Atopic Dermatitis Patient
Patient image

What is the investigational medication?

Amlitelimab is a new drug that is being developed for treating people like you with atopic dermatitis (AD). The drug is not yet approved for treating AD and it can only be used in a study like this.

The investigational medication will be injected under the skin (subcutaneously) during the study.  

Are your AD symptoms still occurring, even with prior treatment?

The purpose of this study is to determine if amlitelimab is an effective and safe treatment in reducing bothersome itching, skin pain and sleeplessness along with frequency and intensity of flare-ups.
Age
12+
Number of visits

Up to 13 visits

Length of study

Up to 13 months

Additional information

66% (2/3) chance of receiving the investigational medication or 33% (1/3) chance of receiving placebo

Clinical Trial Q&A

What is a placebo?

A placebo is an inactive substance or treatment that looks the same and is given in the way as the investigational medication/treatment that is being studied.

What type of study-related medical care is provided during the study?

All study-related medical care related to this study are provided, including study-related exams and study-related medications. All study-related medical care will be explained.

Study may also offer compensation in return for travel.

Are there rules I need to follow if I decided to participate in these studies?

Participation in this study means that you agree to follow certain study rules. Your safety and the ability of the study to produce reliable new knowledge depend on it.

  • Provide truthful information about your AD and other medication conditions along with drugs that you are taking for AD and other conditions.
  • Inform the study doctor before stopping or modifying your AD treatments or before starting any new treatment.
  • Attend the scheduled visits and allow the study test / procedures to be performed, which may include physical exams, blood and urine tests, electrocardiograms (ECG - heart monitoring), questionnaires / diaries.  Optional test / procedures for some studies may include: skin biopsies, blood biomarkers, genetic assessments and skin photos.
  • Inform the study doctor, as soon as possible, of any side effects or health problems that you have, even if you do not think they are because of the study.

Can I speak with someone if I have questions?

Yes, after you complete the online questionnaire and give permission to be contacted, a study representative will contact with you. You can ask questions at any time, before deciding to participate and during study conduct.

Find a site near you

V1.0, 30Jan2024
Images and video property of Sanofi